

GRIFOLS

Grifols and Andorran government agree not to proceed with immunology research center

- *Grifols and Andorra Development and Investment (ADI) have dissolved their joint venture created to oversee the project, the Pyrenees Immunology Research Center*
- *Grifols will further its immunology research at its existing global innovation hubs*
- *The company thanks the Andorran government for its commitment to innovation and science and leaves the door open to future collaborations in healthcare*
- *Grifols has worked with Andorra since the pandemic, when it facilitated tests for the SARS-CoV-2 virus*

Barcelona, Spain, July 25, 2024 – Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino.

Grifols and Andorra Development and Investment (ADI), the principality's economic promotion agency, have decided to formerly dissolve the joint venture established to manage the project, the Pyrenees Immunology Research Center.

Grifols will instead advance its scientific work on immunology as well as other key therapeutic areas through its interconnected network of 13 existing global research centers located in hubs in North America and Europe.

“Grifols would like to thank the Andorran government and everyone who has supported the project for their outstanding commitment to innovation and science,” said Daniel Fleta, Grifols Chief Industrial Services Officer. “Grifols will continue to innovate breakthrough medicines and healthcare solutions through our existing R&D network.”

“While the government of Andorra regrets not being able to move forward with the immunology research center – and we thank Grifols for its collaboration during this time – Andorra remains committed to further diversifying our economy with priority sectors such as biotechnology and other life sciences,” said Conxita Marsol, Andorra's Minister of Presidency, Economy, Work and Housing.

GRIFOLS

Grifols and the Andorran government first began working together during the pandemic, when Grifols facilitated testing for the SARS-CoV-2 virus. They have left the door open to future collaborations in healthcare.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit grifols.com

MEDIA CONTACTS:

Grifols

media@grifols.com

Tel. +34 93 571 00 02

Investors

Investors Relations & Sustainability

GRIFOLS

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

Government of Andorra

Department of Communication - Xavier Palma

comunicacio@govern.ad

Tel. + 376 875 719 / +376 609 500

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.